{"title":"SGLT2抑制剂和室上性心律失常:格列净的抗心律失常作用","authors":"","doi":"10.33140/icvpr.03.01.01","DOIUrl":null,"url":null,"abstract":"Sodium-glucose cotransporter 2 inhibitors are a class of drugs used for the treatment of patients with type 2 diabetes mellitus and heart failure regardless of the coexistence of diabetes. The potential impact of this treatment in patients with heart failure is so huge that they have been named “the statins of the 21st century”. In some studies they appeared to mildly reduce the risk of atrial fibrillation and atrial flutter , however, the available data so fare are scanty.","PeriodicalId":185967,"journal":{"name":"Insights of Cardiovascular Pharmacology Research","volume":"19 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"SGLT2 Inhibitors and Supraventricular Arrhythmias: The Antiarrhythmic Role of Gliflozins\",\"authors\":\"\",\"doi\":\"10.33140/icvpr.03.01.01\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sodium-glucose cotransporter 2 inhibitors are a class of drugs used for the treatment of patients with type 2 diabetes mellitus and heart failure regardless of the coexistence of diabetes. The potential impact of this treatment in patients with heart failure is so huge that they have been named “the statins of the 21st century”. In some studies they appeared to mildly reduce the risk of atrial fibrillation and atrial flutter , however, the available data so fare are scanty.\",\"PeriodicalId\":185967,\"journal\":{\"name\":\"Insights of Cardiovascular Pharmacology Research\",\"volume\":\"19 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Insights of Cardiovascular Pharmacology Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33140/icvpr.03.01.01\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Insights of Cardiovascular Pharmacology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33140/icvpr.03.01.01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
SGLT2 Inhibitors and Supraventricular Arrhythmias: The Antiarrhythmic Role of Gliflozins
Sodium-glucose cotransporter 2 inhibitors are a class of drugs used for the treatment of patients with type 2 diabetes mellitus and heart failure regardless of the coexistence of diabetes. The potential impact of this treatment in patients with heart failure is so huge that they have been named “the statins of the 21st century”. In some studies they appeared to mildly reduce the risk of atrial fibrillation and atrial flutter , however, the available data so fare are scanty.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
